5 min read
Entering Brazil with a biological product is not an extension of what you already know about FDA or EMA biologics pathways. ANVISA has its own review logic, its own sequencing requirements, and its own set of prerequisites that most foreign manufacturers discover later than they should. These are the questions we hear most often — and the answers that change how teams plan their entry.
PATHWAY & ELIGIBILITY
Does my product qualify as a biologic under ANVISA's framework — or does it follow the synthetic pathway?
ANVISA regulates biological products primarily under RDC 55/2010 and its subsequent updates and complementary regulations. The classification depends on the nature of the active substance — not only on the therapeutic category. Products derived from living organisms, including monoclonal antibodies, recombinant proteins, vaccines, and comparable biological products, generally follow the biologics regulatory pathway in Brazil. The distinction matters operationally: the registration process, the dossier structure, and the review timelines differ significantly from the synthetic pathway. If you are uncertain about classification, a pre-submission regulatory assessment is the right starting point.
What is the difference between the biologics registration pathway and the finished product pathway for synthetics?
The most consequential difference is not the dossier format — it is the sequencing logic. The synthetic pathway follows a relatively linear structure. The biologics pathway requires parallel coordination between the BLA application, the GMP process, and ANVISA's review of comparability data. Each track has its own timeline and its own set of prerequisites, and they must converge at the right moment for the marketing authorization to advance. Teams that arrive with a synthetic registration mental model underestimate the coordination the biologics pathway demands.
THE BLA & DOSSIER
What does ANVISA require for the registration of a biological product in Brazil?
For biological products, ANVISA requires the submission of a complete marketing authorization application supported by a CTD-based dossier containing quality, non-clinical, and clinical data, manufacturing information, and evidence of GMP compliance for all applicable manufacturing sites.
Although ANVISA does not officially use the FDA terminology “BLA” (Biologics License Application), the Brazilian biologics registration process is often considered functionally equivalent to a BLA-type submission, since it involves a full regulatory assessment of quality, safety, efficacy, manufacturing, and comparability data for biological products.
What does ANVISA expect in the dossier for a biological product — and how does it differ from FDA or EMA requirements?
ANVISA follows the CTD structure, which aligns with ICH guidelines at the format level. The divergence is in content and local interpretation. ANVISA requires Brazilian-specific administrative documentation, Portuguese labeling aligned with local standards, and in some cases additional clinical data from Brazilian or Latin American populations. For biosimilars, the comparability exercise must meet ANVISA's own guidelines — which are not identical to EMA or FDA biosimilar frameworks. Teams that submit a dossier built entirely to EMA or FDA standards without local adaptation regularly receive deficiency notices on elements that would have passed in other markets.
Can I use my existing CTD dossier for ANVISA, or does it need to be adapted?
Your existing CTD dossier is the right starting point — but adaptation is required, not optional. Module 1 must be entirely rebuilt for Brazil: administrative forms, labeling in Portuguese, local regulatory declarations, and country-specific documentation. Modules 2 through 5 generally transfer, but need to be reviewed against ANVISA's specific technical requirements, particularly for the quality module. If the product has already been approved by recognized reference regulatory authorities such as FDA or EMA, ANVISA may apply reliance-based approaches under the applicable Brazilian regulations, including RDC 741/2022 and related normative instructions. Depending on the product profile and eligibility criteria, certain products may also benefit from prioritization measures under RDC 1001/2025. Eligibility must be assessed on a case-by-case basis depending on the product category, available documentation, and regulatory pathway.
GMP CERTIFICATION & CADIFA
How does ANVISA’s GMP certification process apply to biological products?
ANVISA requires valid GMP certification (CBPF) for all manufacturing sites involved in the production of biological products intended for commercialization in Brazil. Depending on the case, ANVISA may conduct direct inspections or adopt reliance-based evaluation mechanisms supported by inspections conducted by recognized foreign regulatory authorities.
In practice, it is strongly recommended that GMP certification activities be initiated in parallel with the dossier submission process, since ANVISA will require GMP compliance confirmation for all applicable manufacturing sites before granting the marketing authorization.
Does the CADIFA requirement apply to biological APIs, or only to synthetic APIs?
The CADIFA framework under RDC 359/2020 was designed primarily for synthetic APIs. Biological active substances follow a different regulatory pathway — the quality data for the biological API is typically integrated into the BLA dossier rather than submitted as a standalone DIFA. However, if your biological product uses a synthetic API component alongside the biological active substance, a case-by-case assessment should be done to evaluate the necessity of CADIFA. Clarifying the scope early avoids a sequencing problem later.
How do the GMP certificate and the BLA application relate to each other in terms of sequencing?
The BLA application and the GMP certificate request must run in parallel — they cannot be treated as sequential steps. ANVISA will not issue a marketing authorization for a biological product without confirmed GMP compliance for all relevant manufacturing sites. In practice, this means that initiating the GMP certificate request process should happen at the same time as, or before, the BLA submission. Teams that plan to submit the BLA first and then begin the GMP application often encounter an unexpected roadblock: a GMP request is a prerequisite for the BLA submission. Having to initiate the GMP process at that stage can add months to an already lengthy approval timeline.
TIMELINES & DECISION
How long does biologics registration at ANVISA realistically take — and what drives delays?
The official review timeline for biologics at ANVISA varies by product type and classification, but realistic end-to-end timelines — from dossier submission to marketing authorization — typically range from 18 to 36 months. ANVISA's April 2026 Action Plan reported an equilibrium reached in the biologics queue, which signals improved processing. The primary drivers of delay are not the review itself — they are deficiency cycles triggered by incomplete or locally non-adapted dossiers, GMP processes that were not initiated in time, and sequencing errors that create dependency gaps mid-process. The teams that move fastest are the ones that arrive with a complete, adapted dossier and a GMP request already underway.
My company has FDA or EMA approval for this biologic. Does that accelerate the ANVISA process?
It might — but not automatically. ANVISA’s reliance mechanisms under RDC 741/2022 and related normative instructions may allow for a streamlined review for products approved by recognized reference regulatory authorities, including FDA and EMA. Depending on the product profile and eligibility criteria, certain products may also benefit from prioritization measures under RDC 1001/2025.
Eligibility depends on the product category, the scope of the original approval, and whether the dossier submitted to ANVISA meets the local adaptation requirements. These pathways do not eliminate GMP certification requirements (CBPF) or the need for Brazilian-specific documentation. What they may reduce is the depth of ANVISA’s technical reassessment for modules already evaluated by the reference authority, when considered acceptable under the Brazilian regulatory framework.
Assessing eligibility before submission is a step that consistently returns value. Speak with Freyr's Brazil regulatory team to map your BLA and GMP sequence before your planning window closes
